Nuvation Bio Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nuvation Bio Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $7.87M | Mar 2, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $7.87M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 6, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $795.0K | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Mar 6, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($204.63M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($567.94M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($75.80M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($104.20M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($86.85M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($18.22M) | May 21, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($213.06M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($592.63M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($99.82M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($119.73M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($93.32M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($3.06M) | May 21, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $99.12M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $71.29M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $87.82M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $69.04M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $32.60M | Feb 28, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $69.23M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $28.53M | Mar 6, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($173.43M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($130.41M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($68.00M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($96.11M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($68.19M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($880.7K) | May 21, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $594.82M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $540.63M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $621.48M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $672.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $776.15M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $221.79M | Feb 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $289.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $76.84M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $16.36M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $17.07M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $30.15M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $6.71M | Feb 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.72M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $463.79M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $605.12M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $655.08M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $746.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $215.08M | Mar 15, 2023 |
| FY2020 | Apr 23, 2020 | $0 | May 21, 2021 |
| FY2021 | Dec 31, 2019 | $117.75M | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.12B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($910.74M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($342.80M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($267.00M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($162.80M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($75.96M) | Feb 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.09M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $35.72M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $42.65M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $101.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $132.42M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $29.76M | Feb 28, 2022 |
| FY2020 | Apr 23, 2020 | $0 | May 21, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.21M | Mar 2, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 337.84M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 337.84M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 219.05M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 218.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 217.95M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 149.04M | Feb 28, 2022 |